Rheumatology

Diffuse Parenchymal Lung Disease

Questions discussed in this category

When do you begin antifibrotic therapy for a patient with newly diagnosed ILD that is not IPF?

Do you base the decision on FEV1, 6MWD or symptoms at initial evaluation, or progression over time?

4 Answers available

Do you consider the use of antifibrotics at presentation in patients with a radiographic UIP pattern of pulmonary fibrosis in the presence of positive serologies without any symptoms of CTD (ie, fulfilling a possible diagnosis of IPAF) who have not yet demonstrated evidence of a progressive phenotype?

1 Answer available

Papers discussed in this category

The European respiratory journal, 2015-10

An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features.

N Engl J Med, 2019 Sep 29

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.

Arthritis & rheumatology (Hoboken, N.J.), 2017-03

Progressive Decline of Lung Function in Rheumatoid Arthritis-Associated Interstitial Lung Disease.

N. Engl. J. Med., 2019 May 20

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.

Related Topics in Rheumatology